Caregiver‐reported increased food motivation and adiposity in dogs receiving antiseizure drugs Authors: Anna Morros‐Nuevo, Rowena M A Packer, Nicole Regan, Eleanor Raffan Published: 2024 ABSTRACT AbstractBackgroundIdiopathic epilepsy is the most common chronic neurological disease in dogs and requires lifelong administration of antiseizure drugs (ASD). A decreased level of energy and increased food intake and weight gain have been described as long‐lasting side effects.MethodsWe assessed food motivation (FM), using the previously validated dog obesity risk assessment questionnaire, in dogs diagnosed with idiopathic epilepsy (n = 222) and healthy dogs (n = 7086) to determine if epilepsy and ASD were associated with increased FM and adiposity and decreased activity. We also assessed how caregivers managed weight gain in this population of dogs in the study.ResultsDogs with idiopathic epilepsy receiving ASD had significantly higher FM than healthy dogs. Their carers also reported significantly greater interventional effort and food restriction compared with healthy dogs, yet they had significantly higher adiposity. Minimal modelling showed that within the epileptic group, ASD had the highest impact on FM, with an effect size of 32%.LimitationsCarer‐reported data were used, which could have introduced bias. Furthermore, the sample size did not allow us to distinguish the effect of individual ASD.ConclusionsASD increases FM in dogs, resulting in greater adiposity.Keywords: dogs, epilepsy, obesity, owner attitudes to pets, veterinary profession INTRODUCTION Idiopathic epilepsy (IE) is the most common chronic neurological disease in dogs, with an estimated prevalence of 0.6%. 1 Historically, the primary aim of treating dogs with epilepsy has been reducing the frequency and severity of seizures, which is most commonly achieved with the use of antiseizure drugs (ASD). 2 Despite this goal, ASD therapy rarely leads to seizure freedom, 3 and many dogs receiving long‐term ASD treatment experience adverse effects during the interictal period. In recent studies, over 80% of caregivers of dogs administered ASD reported ataxia, lethargy and increased thirst and appetite. 4 Such effects are more commonly reported in patients treated with a combination of more than one ASD (polytherapy) 4 , 5 , 6 and are a key concern for owners of epileptic dogs. 7 Furthermore, given that the probability of seizure control diminishes progressively with successive ASD treatments, 8 postictal signs (e.g., restlessness and temporary blindness), which have a negative impact on quality of life (QoL), might not be deterred by the use of ASD. 9 In people with epilepsy, ASD adverse effects are negatively associated with self‐reported QoL, having a greater impact than seizure frequency. 10 Similarly, in dogs with epilepsy, data suggest that caregiver‐reported QoL scores are significantly lower in dogs experiencing ASD adverse effects than those that are not. 4 , 11 To reliably address ASD adverse effects in research (e.g., drug development and clinical trials) and in practice (e.g., finding a balance between seizure control and adverse effect severity), methods for objective quantification of adverse effects are required. Increased interest in food is a frequently cited ASD adverse effect. 12 This has commonly been referred to in the literature as ‘polyphagia’ or ‘hyperphagia’, terms that strictly imply increased food intake but are commonly used in the veterinary literature to describe excessive food drive or appetite, 13 , 14 largely because there has not been a well‐defined measure of the drive to eat in dogs. An increased desire to eat (where ad libitum food is not available, as in most homes where pet dogs are kept) has been proposed as a source of primary, negative emotions, 14 which may impact QoL if it becomes chronic. Excessive drive to eat may lead to undesirable behaviours such as begging and scavenging, which can have a negative impact on the dog‒caregiver bond. 15 , 16 In addition, increased food drive or food motivation (FM) may also lead to further medical issues related to overeating and obesity, especially in combination with reduced physical activity, which is another common ASD side effect. 15 , 16 , 17 , 18 In turn, obesity is associated with reduced lifespan and poor QoL 19 , 20 and predisposes individuals to health conditions including orthopaedic and respiratory diseases, urinary incontinence and dyslipidaemia. 21 , 22 , 23 , 24 , 25 , 26 , 27 Despite the potential consequences of ASD‐related increased FM for dogs and their caregivers, to the authors' knowledge, there are no published attempts to quantify this common adverse effect or understand caregiver management of weight and FM in dogs with epilepsy. This likely reflects having limited tools to measure such effects and differences in their perceived importance between stakeholder groups. For example, in a recent study, caregivers and veterinarians working in general practice ranked adverse effects of ASD and why they occur as a higher priority research area for canine epilepsy than specialist veterinary neurologists, 28 a finding that has also been observed in human medicine. 29 We previously developed a validated measure of canine FM and owner management practices: the dog obesity risk assessment (DORA) questionnaire. The questionnaire asks dog caregivers to respond to a series of statements about their dogs’ behaviour around food and their management of diet and exercise using a Likert scale. It has been shown to be repeatable and suitable for administration at scale, enabling systematic use in large clinical populations. A high ‘food motivation score’ (FMS, scale 0‒1) suggests that dogs persistently seek food in the home environment through both proximity and ‘begging’‐type behaviours. 30 The use of the questionnaire has contributed to evidence that highly food‐motivated dogs are at risk of developing obesity and that FM varies between breeds and with age, sex and neuter status. 30 , 31 We hypothesised that (1) the previously reported ‘hyperphagia’ or ‘polyphagia’ in dogs receiving ASD would be quantifiable as an increase in FMS relative to control dogs; (2) that ASD polytherapy would be related to a greater increase in FM than monotherapy; and (3) that owner management efforts to control weight will increase with increasing dog FM. METHODS Data collection and curation This project was approved by the Social Science Research Ethical Review Committee at the Royal Veterinary College, London, UK. Caregivers of epileptic dogs aged between 1 and 20 years were recruited online via social media platforms and forums between July and August 2018. Caregivers of healthy (control) dogs were recruited through the same method between May 2015 and October 2021. Inclusion and exclusion criteria For both groups, the following exclusion criteria were applied: Dogs that suffered medical conditions other than IE or were taking medications other than ASD that could affect weight, FM or activity levels were excluded. These medications included, but were not limited to, corticosteroids and medications used to treat thyroid disease, diabetes and hyperadrenocorticism (Supporting Information, Section 1). Dogs that suffered medical conditions other than IE or were taking medications other than ASD that could affect weight, FM or activity levels were excluded. These medications included, but were not limited to, corticosteroids and medications used to treat thyroid disease, diabetes and hyperadrenocorticism (Supporting Information, Section 1). Body condition score (BCS, 1–9) is a measure of canine adiposity based on haptic and visual cues, 32 , 33 where 5 represents ideal bodyweight and every point above that corresponds to an ∼8% increase in adiposity. 33 , 34 Dogs with a BCS of 3 or lower were excluded, as this value is considered underweight and may be indicative of underlying health conditions (Supporting Information, Section 3). Body condition score (BCS, 1–9) is a measure of canine adiposity based on haptic and visual cues, 32 , 33 where 5 represents ideal bodyweight and every point above that corresponds to an ∼8% increase in adiposity. 33 , 34 Dogs with a BCS of 3 or lower were excluded, as this value is considered underweight and may be indicative of underlying health conditions (Supporting Information, Section 3). To be included in the epileptic group, dogs had to meet Tier I confidence level for the diagnosis of IE (hereafter referred to as the ‘epileptic group’); that is a history of two or more unprovoked epileptic seizures occurring at least 24 hours apart (in some but not all cases including review of video footage of the seizures by a veterinarian, which is consistent with the Tier 1 criteria), an age between 6 months and 6 years when the first seizure occurred, and normal neurological examination, blood tests and urinalysis that show no discernible cause for the seizures. 2 Matched control selection The control group was selected at random except that we enriched for breeds which were most commonly represented in the case group, because breed has previously been associated with food motivation. 30 , 35 , 36 Despite this, some breeds were still more common in the case compared to the control group. We note that the distribution of sex and neuter status was similar between control and case groups, which is important because those factors are also associated with food motivation. 31 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 Survey design The participants were invited to complete an online survey published through commercially available software, 47 which was structured in four sections (Supporting Information, Section 2): Signalment and clinical history Signalment and clinical history DORA questionnaire DORA questionnaire Identification of their dog's BCS from a visual scale Identification of their dog's BCS from a visual scale Perceived ASD impact on behaviour and FM (epileptic group only) Perceived ASD impact on behaviour and FM (epileptic group only) Statistical analysis Statistical analysis was performed with R Studio (version 4.3.1). 48 Univariate statistical analysis with Holm correction was used to assess differences in age, BCS and DORA scores between groups (epileptic vs. control) and, within the epileptic group, between drug‐naïve dogs and those receiving monotherapy or polytherapy. Pearson's correlations were used to analyse how side effects, BCS and FMS correlated with the number of ASD taken. To assess the combined effect of ASD and factors predicted to alter eating behaviour within the epileptic group, minimal modelling was performed using Akaike's information criterion (Supporting Information, Section 4). RESULTS Population features Two hundred and twenty‐two dogs of various breeds were included in the epileptic group (Table S2), of which 86 were female (11.6% entire and 88.4% neutered) and 136 were male (25.7% entire and 74.3% neutered). From an initial database of over 19,000 responses, the final number of subjects remaining in the control group was 7086 after applying inclusion and matching criteria, of which 3036 were female (11.7% entire and 88.3% neutered) and 4050 were male (30.9% entire and 69.1% neutered). The mean age (± standard deviation [SD]) did not differ significantly between epileptic and control groups (5.50 ± 3.58 years and 5.64 ± 4.78 years, respectively). Crossbred dogs were the most common type in both the epileptic (24.77%) and control groups (25.15%). Border Collies and ‘other purebreds’ were overrepresented in the epileptic group (16.67% and 10.81%, respectively) compared with the control group (6.46% and 7.30%, respectively). Within the epileptic group, eight (3.6%) dogs were drug naïve, 80 (36%) received monotherapy and 134 (60.4%) received polytherapy. The most common ASD used within the epileptic group was phenobarbital (n = 179, 80.6%), followed by potassium bromide (n = 90, 40.5%), levetiracetam (n = 83, 37.4%), imepitoin (n = 27, 12.2%), zonisamide (n = 21, 9.5%), gabapentin (n = 8, 3.6%), clorazepate (n = 4, 1.8%) and topiramate (n = 1, 0.5%). The mean age (± SD) at the onset of seizures was 2.68 ± 1.51 years. The mean duration of treatment (± SD) varied by drug, with levetiracetam having the shortest duration (15.6 ± 18.1 months) and phenobarbital the longest (86.1 ± 76.1 months). BCS, FMS and owner management factors Compared to the control group, epileptic dogs receiving ASD had significantly higher BCS (p < 0.001), FMS (p < 0.001) and FMS subcomponents: responsiveness and satiety (p < 0.001), lack of fussiness (p < 0.001) and interest in food (p < 0.001). Epileptic dogs also had significantly higher owner intervention scores (p < 0.002) and restriction of human food scores (p < 0.001) and significantly lower exercise scores (p < 0.001). The overall owner control score, which combines the intervention score, restriction of human food score and exercise score, did not differ significantly between groups (Figure 1; Supporting Information, Section 6, Tables S3 and S4). Box and whiskers plots showing body condition scores (a) and dog obesity risk assessment (DORA) scores for food motivation (b) and its subcomponents (b1‒b3) and owner control (c) and its subcomponents (c1‒c3) in healthy control dogs, drug‐naive dogs with idiopathic epilepsy (IE), dogs with IE receiving antiseizure drug (ASD) monotherapy and dogs with IE receiving ASD polytherapy. The box represents upper and lower quartile values with the median shown in the middle and the mean represented with a red dot. The vertical line represents minimum and maximum data value and individual scores and are shown as black dots. The level of significance (t‐test) is shown as ‘ns’ (p > 0.05), * p < 0.05, ** p < 0.01 or *** p <0.001 ASD side effects and dietary management Most caregivers reported never using extra treats because their dog had epilepsy (70.0%) or giving extra treats before (71.6%) or after (40%) their dog had a seizure. However, many always used treats to administer their dog's ASD medication (53.0%) and did not compensate for it by reducing the dog's main food ratio (33.8%) (Figure 2; Table S5). Bar plots showing the number of participants who reported ‘never’, ‘rarely’, ‘sometimes’ ‘often’ or ‘always’ (a) giving extra treats to their dogs because they have epilepsy, (b) giving treats because they are going to have a seizure, (c) giving treats because they had a seizure, (d) using treats to administer ASD and (e) altering meals to compensate for treats Phenobarbital was most commonly reported as being associated with side effects (n = 92/179, 51%), followed by imepitoin (n = 8/27, 29%), potassium bromide (n = 19/90, 21%), zonisamide (n = 4/21, 19%) and levetiracetam (8/83, 9%). Most respondents considered increased hunger as a side effect of ASD but not increased food intake (Figure 3; Table S6). Bar plots showing the number of participants who considered it ‘not at all true’, ‘somewhat true’, ‘mainly true’ or ‘definitely true’ that ASD (a) resulted in a decrease in their dog's coordination, (b) decreased level of energy to play, (c) increased hunger or (d) increased food intake ASD, FMS and obesity There were only eight drug‐naïve epileptic dogs (four Border Collies, one Boston Terrier, two crossbreeds and one West Highland White Terrier), and they showed no significant differences in BCS and FMS when compared with control dogs. However, the control group had significantly higher lack of fussiness (p = 0.036) and interest in food (p = 0.012) scores. Negative results were to be anticipated due to the analysis being underpowered, with a post hoc power calculation showing that we would require 20 times more drug‐naïve epileptic dogs to detect small differences between the two populations. 49 , 50 The unequal sample sizes might reduce power because smaller samples provide less precise estimates of group means, and the t‐statistic becomes less sensitive to true mean differences due to the weight of the smaller sample size. 51 , 52 However, we compared drug‐naïve epileptic dogs against all epileptic dogs receiving ASD and found that dogs receiving ASD had significantly higher FMS (p = 0.002) and its subcomponents: responsiveness and satiety (p = 0.022), lack of fussiness (p = 0.001) and interest in food (p = 0.002). There were no significant differences in BCS and age (Figure 1; Tables S3 and S4). We then compared epileptic dogs receiving monotherapy with those receiving polytherapy and found no significant differences (Figure 1; Tables S3 and S4). Since this binary classification of monotherapy versus polytherapy is crude, we also considered whether the number of drugs might be significant. The number of drugs used varied considerably (0 ASD: n = 8; 1 ASD: n = 80; 2 ASD: n = 82; 3 ASD: n = 40; 4 ASD: n = 11; 5 ASD: n = 1) and was significantly positively correlated with carers' reports of decreased energy (r = 0.30, p < 0.001), decreased coordination (r = 0.43, p < 0.001) and increased owner perception of dogs’ hunger (r = 0.18, p = 0.007). It was not significantly correlated with perceived increase in food intake, FMS, responsiveness and satiety score and interest in food score, but it was significantly but weakly positively correlated with BCS (r = 0.14, p = 0.032) and lack of fussiness score (r = 0.15, p = 0.026). Sex, neuter status and ASD explain the majority of variability in FMS Within the epileptic group, the minimal model for FMS (initially containing sex, age and neuter status, allowing two‐way interactions) retained sex and neuter status as significant variables, which explained 1.8% of the variability. Adding ASD (receiving ASD: yes and no) to the model increased variability explained to 8.9%, and ASD remained significant (β = 0.32, p < 0.001), alongside sex (β = ‒1.17, p = 0.042) and the interaction between sex and neuter status (β = 0.23, p = 0.012) (Table S1). DISCUSSION This survey of the effect of epilepsy and ASD on FM in dogs identified that epileptic dogs receiving ASD tend to be more food motivated. The data suggest that ASD are responsible for the changes shown, not epilepsy per se, although the study was underpowered to prove that. We further show that caregivers of dogs receiving ASD tend to restrict their dogs’ access to food more assiduously than caregivers of non‐epileptic dogs, but despite this, epileptic dogs receiving ASD tend to have greater BCS. Our data are consistent with previous reports that treatment with ASD is associated with increased food drive, hunger or similar terms reported across different studies. 53 A previous review found that 29‒44% of studies reported polyphagia in dogs treated with one of a number of commonly used ASD. 53 Another systematic review of the safety of potassium bromide found that 15% of publications provided primary evidence regarding polyphagia as an adverse effect in dogs. 54 However, such studies provide no detail on the percentage of all reviewed dogs affected and tend to use unvalidated measures of food intake, food drive and hunger. Our data capitalised on a previously validated measure of canine eating behaviour 30 and benefitted from a large, breed‐matched control population; therefore, our findings robustly demonstrate that ASD are associated with greater FM in the home environment. The authors acknowledge that the inclusion of IE dogs over a wide age range (1‒20 years) means that some dogs may have undiagnosed comorbidities that could affect the data. Similarly, despite all IE dogs having Tier 1 diagnoses according to the International Veterinary Epilepsy Task Force consensus report on epilepsy definition, it is possible that some might have pathologies which can occasionally meet these criteria, and information about the onset of the first seizure at the time of diagnosis is lacking. However, despite these possible confounders, the results remain clear. A common limitation in ASD studies is the difficulty of distinguishing which is the causative drug when it is used as part of polytherapy. Chang et al. 7 found that polyphagia was 30% higher in dogs receiving phenobarbital monotherapy than potassium bromide monotherapy. However, in dogs receiving a combination of the two drugs, the results are less consistent, suggesting that it is a combined effect of both drugs that results in increased ‘polyphagia’. Similarly, in our population, most participants considered that phenobarbital affected appetite the most, followed by potassium bromide. However, those were also the most common ASD, and the study was insufficiently powered to statistically compare the effect of individual ASD on FM and adiposity. When we compared epileptic dogs receiving ASD monotherapy or polytherapy as a binary characteristic, our data showed no significant differences in BCS, FMS and its subcomponents, but the number of ASD was positively correlated with a perceived decrease in energy and coordination, increased hunger but not food intake, and decreased lack of fussiness score, suggesting that polytherapy might be associated with greater side effects. This was a secondary analysis, and the study was not designed to test the effect of monotherapy versus polytherapy on FM and obesity, so the absence of other significant differences does not rule out that they might exist. Likewise, it seems unlikely that dogs receiving ASD who are reported to have increased hunger do not have a parallel increase in food intake, as owners have been shown to perform poorly at limiting food availability. 55 This trend is further impacted by the fact that a majority of dog carers rely on food to help administer their dog's ASD medication. Epileptic dogs treated with ASD commonly receive oral medication every 8‒12 hours, which has a potentially large accumulative impact on calorie input. Furthermore, a recent study 56 found that a large proportion (45.8%) of carers of dogs with epilepsy give their dog dietary supplements in an attempt to manage their epilepsy, with these supplements commonly belonging to the fatty acid group, which is highly calorific. Cumulatively, these attempts to control seizure frequency and/or severity could result in a large daily intake of calories in addition to these dogs' base diets. Although polyphagia is associated with commonly administered ASD, 4 it is sometimes considered transient, with reports suggesting it to be at greatest intensity in the first 2‒4 weeks of treatment and subsiding after this period once serum levels reach a steady state 57 , 58 , 59 (although that is not always the case 60 ). Our cross‐sectional dataset did not allow us to identify longitudinal changes over time, but a previous study by Boothe et al. 57 compared the proportion of dogs exhibiting polyphagia 1 and 6 months after starting treatment and identified a significant decrease in proportion over that time, from 30% to 0% for dogs receiving phenobarbital and 39% to 4.3% for dogs receiving potassium bromide. This is in accordance with another study 5 where polyphagia was found to be the most common and severe side effect reported, and on average, it reduced in severity after the first 2 weeks. That study also revealed that the median score of polyphagia was greater in polytherapy than in monotherapy cases, supporting our findings that increased numbers of ASD were significantly positively correlated with increased perceived hunger, lack of fussiness (related to food) and BCS. Overall, our results empirically corroborate existing data that ASD therapy increases FM in dogs, even after a protracted treatment period. Epilepsy and obesity Dogs with epilepsy are potentially predisposed to become obese not only due to the combined effects of polyphagia and reduced activity (sedation) from ASD but possibly because of the physical and psychological stress caused by the condition itself. 9 , 61 In a survey of caregivers, it was found that dogs with chronic poor health showed more signs of stress‐induced emotional eating. 55 However, it is possible that these participants were required to pay more attention to their dog's diet and feeding habits, resulting in inaccurately reported emotional eating. Rowland and Antelman 62 demonstrated that, in rats, polyphagia can be induced by chronic stress (mild tail pinches several times a day) and, through analysis of hair cortisol levels, dogs with epilepsy have been shown to experience chronic stress compared to non‐epileptic dogs. Epileptic dogs receiving ASD might also suffer from chronic hunger, contributing to chronic stress levels. Indeed, a study by Sandilands et al. 63 found that blood indices of stress were higher in broiler chickens experiencing chronic hunger due to feed restriction, and there is evidence of increased glucose utilisation within the brain during and immediately after a seizure in people, 64 which may, in turn, contribute to increased hunger. Only dogs with a BCS of more than 4 were included in our study, which aimed to exclude dogs in which comorbidities or persistent seizures might confound the effect of ASD on eating behaviour because their low body condition might be driving hyperphagia or be a reflection of poor appetite related to systemic conditions. We believe that our data are representative of the most common form of IE and may provide a higher BCS estimate population wide. In people, obesity and epilepsy are comorbid, with several mechanisms for this association proposed, including (1) ASD stimulating appetite; (2) reduced physical activity of epileptic patients; (3) seizures disrupting hormone systems related to energy intake, metabolism and expenditure 65 ; and (4) obesity priming the brain for seizures. 65 In accordance with previous studies, 4 our data support that dogs receiving ASD tend to have higher BCS, which might be in part mediated by increased FM and decreased exercise levels. 66 However, due to the small sample size, the effect of epilepsy and ASD cannot be distinguished in our sample population. Lethargy is a common side effect of ASD treatment. 12 It is therefore also possible that as well as being a method of coping with stress, dogs with epilepsy are eating more due to boredom/frustration caused by lethargy. Furthermore, exercise has also been suggested to have an effect on reducing stress. Unsurprisingly, in our epileptic population, Border Collies were overrepresented, 4 but interestingly, this breed has a low average FMS and obesity probability and tends to be more active 67 ; however, this group had significantly higher FMS and BCS and significantly lower exercise levels than healthy dogs. Given that owner‐reported BCS was used in this study, which is known to be biased towards a more ideal value, 68 , 69 , 70 , 71 , 72 it is likely that BCS differences are underestimated. Previous studies have reported risk factors for obesity such as sex, neuter status, age and breed. 31 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 73 Our results showed that sex, age and neuter status explained less than 2% of the variability in FM within the epileptic group. However, when ASD (receiving or not receiving ASD) was added to the model, the variability explained increased to 8.9%, and the use of ASD had the largest significant positive effect, with the potential to increase FMS by 32%. Unfortunately, this model only contained eight drug‐naïve epileptic dogs; therefore, these results must be interpreted carefully. Epilepsy and owner management of weight and appetite Owners tend to underestimate their pets' weight status 68 , 69 , 70 , 71 , 72 and overestimate exercise levels. 74 , 75 White et al. 72 reported that only half of the dog owners they surveyed agreed with their vet on the degree to which their pet was overweight; while some recognised that their dog had a weight problem, they preferred to classify it as overweight rather than obese. However, differences between epileptic and healthy dogs are being identified by our participants. The epileptic dogs in our study were perceived as exercising significantly less and having significantly greater FM and significantly higher adiposity. Our data also show that owners of epileptic dogs apply more self‐reported food restrictions and interventional efforts than owners of healthy dogs, but the overall management remains the same. This finding suggests that owners of epileptic dogs receiving ASD recognise that their dogs are more food motivated and less active and try to compensate for it by managing their diet. Nonetheless, the differences in BCS show that they fail in their efforts to keep their dog's weight down, in accordance with previous findings in the general canine population. CONCLUSION In conclusion, dogs taking ASD are more food motivated and have greater adiposity than healthy dogs. Dogs with epilepsy are also reported to exercise less, and although caregivers compensate for this by restricting food more, their overall efforts to control weight appear to be ineffective. Sources of additional calories that may be thwarting owners' attempts to control their dog's weight were identified, particularly using treats to administer dogs’ ASD twice or more per day. Given the potential negative impacts of obesity, owners of dogs with epilepsy should be counselled on the impact of ASD on FM when first offered as treatment and should be offered support (e.g., weight clinics) to monitor their dog's BCS while receiving ASD. AUTHOR CONTRIBUTIONS Conceptualisation and design of the work: Rowena M.A. Packer, Anna Morros‐Nuevo and Eleanor Raffan. Data acquisition: Nicole Regan, Rowena M.A. Packer and Eleanor Raffan. Methodology: Anna Morros‐Nuevo, Rowena M.A. Packer and Eleanor Raffan. Data analysis: Anna Morros‐Nuevo and Nicole Regan. Interpretation of data: Anna Morros‐Nuevo, Rowena M.A. Packer, Nicole Regan and Eleanor Raffan. Visualisation: Anna Morros‐Nuevo and Nicole Regan. Drafted work: Rowena M.A. Packer, Eleanor Raffan, Anna Morros‐Nuevo and Nicole Regan. Revised work: Eleanor Raffan and Rowena M.A. Packer. Founding acquisition: Rowena M.A. Packer, Eleanor Raffan and Anna Morros‐Nuevo. Writing: Anna Morros‐Nuevo, Eleanor Raffan and Rowena M.A. Packer. CONFLICT OF INTEREST STATEMENT The authors declare they have no conflicts of interest. ETHICS STATEMENT This project was approved by the Social Science Research Ethical Review at the Royal Veterinary College, London, UK. Supporting information Supporting Information ACKNOWLEDGEMENTS We are indebted to the owners who volunteered for the study and to the dogs who took part. E.R.’s post is supported by the Wellcome Trust Clinical Research Career Development Fellowship (award 205187/Z/16/Z), A.M.N.’s post is supported by the Morris Animal Foundation (award D22CA‐406), R.P. received funding from the Biotechnology and Biological Science Research Council (grant number BB/P010881/1) and N.R. received a UFAW Animal Welfare Student Scholarship that allowed her to take part in this project. The founders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Morros‐Nuevo A, Packer RMA, Regan N, Raffan E. Caregiver‐reported increased food motivation and adiposity in dogs receiving antiseizure drugs. Vet Rec. 2024;e4907. 10.1002/vetr.4907 DATA AVAILABILITY STATEMENT The datasets generated and/or analysed during the current study are available in the Apollo, University of Cambridge repository (https://doi.org/10.17863/CAM.106981). REFERENCES Associated Data Supplementary Materials Supporting Information Data Availability Statement The datasets generated and/or analysed during the current study are available in the Apollo, University of Cambridge repository (https://doi.org/10.17863/CAM.106981).